Taysha Gene Therapies, Inc. (TSHA)
NMS – Real vaqt narxi. Valyuta: USD
6.34
+0.13 (2.09%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
6.26
-0.08 (-1.22%)
Bozordan keyin: Jun 26, 2026, 7:59 PM EDT
Find any stock by ticker or company name

NMS – Real vaqt narxi. Valyuta: USD
6.34
+0.13 (2.09%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
6.26
-0.08 (-1.22%)
Bozordan keyin: Jun 26, 2026, 7:59 PM EDT
Taysha Gene Therapies, Inc., klinik tadqiqot bosqichidagi biotexnologiya kompaniyasi, markaziy asab tizimining og'ir monogen kasalliklarini davolash uchun adeno-assotsiatsiyalangan virus asosidagi gen terapiyalarini ishlab chiqish va tijoratlashtirishga qaratilgan. Kompaniya asosan gigant aksonal neyropatiyani davolash uchun TSHA-120; Rett sindromini davolash uchun TSHA-102; CLN7 kasalligini davolash uchun TSHA-121; CLN1 kasalligini davolash uchun TSHA-118; SLC13A5 etishmovchiligini davolash uchun TSHA-105; tauopatiyalarni davolash uchun TSHA-113; Angelman sindromini davolash uchun TSHA-106; va mo'rt X sindromini davolash uchun TSHA-114ni ishlab chiqadi. Kompaniya Texas universiteti janubi-g'arbiy tibbiyot markazi bilan tadqiqot, hamkorlik va litsenziyalash bo'yicha kelishuvga ega. Taysha Gene Therapies, Inc. 2019-yilda tashkil etilgan va Dallas, Texasda joylashgan.
| Ism | Lavozim |
|---|---|
| Berge Minassian M.D. | Chief Medical Advisor of UT Southwestern Gene Therapy Program |
| Dr. Steven Gray Ph.D. | Chief Scientific Advisor of UT Southwestern Gene Therapy Program |
| Dr. Sukumar Nagendran M.D. | President, Head of Research & Development and Director |
| Hayleigh Collins | Director of Corporate Communications & Investor Relations |
| Mr. Frederick Porter Ph.D. | Chief of Staff & Technical Operations Officer |
| Mr. Kamran Alam CPA, M.B.A. | CFO & Corporate Secretary |
| Mr. Sean McAuliffe | Chief Business Officer |
| Mr. Sean P. Nolan | CEO & Chairman |
| Ms. Emily McGinnis M.P.H. | Chief Patient & External Affairs Officer |
| Ms. Rumana Haque-Ahmed | Chief Regulatory Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-06-22 | 8-K | d20817d8k.htm |
| 2026-06-02 | 8-K | d159199d8k.htm |
| 2026-05-06 | 8-K | d99032d8k.htm |
| 2026-05-06 | 10-Q | tsha-20260331.htm |
| 2026-04-22 | DEFA14A | d139508ddefa14a.htm |
| 2026-04-22 | DEF 14A | d94391ddef14a.htm |
| 2026-04-22 | ARS | d942601dars.pdf |
| 2026-03-19 | 8-K | d46409d8k.htm |
| 2026-03-19 | 10-K | tsha-20251231.htm |
| 2026-01-06 | S-8 | d20072ds8.htm |